Health ❯ Biotechnology

Drug Development

Clinical Trials Therapeutics Gene Therapy Immunotherapies Company Closures Clinical Testing AI in Healthcare Clinical Efficacy Weight Loss Drugs Cancer Treatment Cardiovascular Drugs Protein Applications Obesity Treatments Immunotherapy Alzheimer's Drugs Cancer Research Biologics Research Investments Vaccine Design Clinical Research Allosteric Modulators Research Capabilities Antibodies Protein Therapeutics Press Releases Biosimilars Vaccine Research Neurodegenerative Disorders Regulatory Affairs Monoclonal Antibodies Viral Hepatitis Molecular Transport

ImmunityBio Investors Face May 26 Lead-Plaintiff Deadline in Securities Suit Tied to FDA Anktiva Rebuke

The case stems from an FDA warning that promotional claims for Anktiva were false or misleading, which drove a roughly 21% stock drop on March 24.

ImmunityBio Investors Urged to Seek Lead Role in Suit After FDA Rebuke Over Anktiva Ads

Senhwa Signs MOU With GEM for Up to NT$500 Million to Speed AI-Driven Cancer R&D

Nuclera Extends Series C to $87 Million to Accelerate Full-Format Antibody Workflows

Sanofi Secures Global Rights to ADEL’s Alzheimer’s Antibody in Deal Worth Up to $1.04 Billion

Prolynx Raises $70 Million to Advance Ultra-Long-Acting Obesity Drugs

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Lilly and Breakthrough to Open Gateway Labs Biotech Incubator at 2300 Market in Philadelphia

FDA Flags Possible License Revocation for Sarepta’s Elevidys